VTYX Stock Recent News

Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy candidate is VTX002 to treat moderate-to-severe ulcerative colitis.

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Start Time: 16:30 January 1, 0000 5:23 PM ET Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Raju Mohan - Founder and CEO Marty Auster - CFO Bill Sandborn - President and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.

Ventyx's shares shot up while insiders were selling. The company is a clinical-stage biotech.

Ventyx Biosciences, Inc. has a number of interesting assets in mid-stage trials. The company is founded by a successful serial entrepreneur. Phase 2 data later this year will be pivotal for Ventyx Biosciences prospects.

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Derek Archila - Wells Fargo Alex Thompson - Stifel Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.

ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

Where is the current bull market? All indications would be that it's in biotech!

The stock price of Ventyx Biosciences Inc (NASDAQ: VTYX) fell by over 4% intraday today. This is why.

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.